Grand Rounds in Urology (GRU) Webinar

Wednesday, June 30th 6-7pm ET

Join Dr. Edward Uchio for a discussion on the use of the Oncotype DX GPS assay in patients with favorable intermediate-risk prostate cancer.

ASCO21 Virtual Scientific Program

Abstracts Available

Exact Sciences strengthens evidence supporting Cologuard and Oncotype DX tests and deep oncology pipeline with multiple data presentations.

Medical Lab Professionals Week: Pathologist Webinar

Available On-Demand

You can still see Drs. Rick Baehner and Josh Routh's webinar reviewing the Oncotype MAP Pan-Cancer Tissue Test: Validation and Clinical Utility in Solid Tumors from a Pathologist's Perspective.

New NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score® Test as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer.

20-Year Outcomes

Oncotype DX Genomic Prostate Score

New follow-up data suggests that the GPS result may be associated with prostate cancer outcomes for up to 20 years after diagnosis.

Landmark RxPONDER Trial Results

Presented at SABCS 2020

New data clarifies the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Recurrence Score® results of 0 to 25

Shaping Clinical Practice: ADAPT and RSClin

Presented at SABCS 2020

Individualized absolute chemotherapy benefit for node-negative breast cancer patients

Medicare Coverage Update

Oncotype DX Genomic Prostate Score

The Oncotype DX Genomic Prostate Score Assay is now covered by Medicare for all intermediate-risk prostate cancer patients.
Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.